Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704

PURPOSE: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from this study also provide information about predictors of recurrence that may be used to tailor indiv...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Adv Radiat Oncol
Hlavní autoři: Regine, William F., Winter, Kathryn, Abrams, Ross A., Safran, Howard, Kessel, Ivan L., Chen, Yuhchyau, Fugazzi, James A., Donnelly, Eric D., DiPetrillo, Thomas A., Narayan, Samir, Plastaras, John P., Gaur, Rakesh, Delouya, Guila, Suh, John H., Meyer, Joshua E., Haddock, Michael G., Didolkar, Mukund S., Padula, Gilbert D.A., Johnson, David, Hoffman, John P., Crane, Christopher H.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2018
Témata:
Pancreas Tumor
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000159/
https://ncbi.nlm.nih.gov/pubmed/29904740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.adro.2018.01.003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky